SPRO - Spero Therapeutics Annual Revenue Growth (Last Twelve Months)

Graphic logo of Spero Therapeutics (SPRO)

Spero Therapeutics revenues rely on long-term patent protection for antibiotics and stable hospital demand. The last twelve months (LTM) commercial revenue growth rate on the GURU.Markets terminal linear chart reflects business dynamics, where 36.20 serves as the current parameter value. However, commercial success is limited by the high cost of new drugs and insurance complexities, although the brand's strong medical reputation sustains investor confidence.

Spero Pharma (SPRO) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 11/18/2026

Summary analytical data breakdowns for Spero Therapeutics Inc (SPRO)

- current price and projected stock value:
Analysis of all company metrics:Spero, SPRO
Signature product of Spero Therapeutics, Inc.

Revenue dynamics for Spero Therapeutics (SPRO) depend directly on the commercialization efficiency of its drugs. This TTM year-over-year revenue change metric measures the sales growth rate while smoothing out short-term volatility. The upward trend confirms the success of hiring drug promotion specialists. However, peak values may signal an overvaluation of the asset. A stable staff of microbiologists provides the foundation for long-term business scaling.